Exagen Inc (XGN) - Total Liabilities
Based on the latest financial reports, Exagen Inc (XGN) has total liabilities worth $37.52 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Exagen Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Exagen Inc's total liabilities have evolved over time, based on quarterly financial data. See Exagen Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Exagen Inc Competitors by Total Liabilities
The table below lists competitors of Exagen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
USA | $41.25 Million |
|
Orian Sh.M. Ltd
TA:ORIN
|
Israel | ILA390.57 Million |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
USA | $17.96 Million |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
Malaysia | RM463.23 Million |
|
Lemonsoft Oyj
HE:LEMON
|
Finland | €21.66 Million |
|
MLRN Projects and Trade Ltd
TA:MLRN
|
Israel | ILA807.85 Million |
|
Active Biotech AB
ST:ACTI
|
Sweden | Skr12.50 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Exagen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Exagen Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Exagen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Exagen Inc (2012–2025)
The table below shows the annual total liabilities of Exagen Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $40.57 Million | +15.43% |
| 2024-12-31 | $35.15 Million | +2.62% |
| 2023-12-31 | $34.25 Million | -21.73% |
| 2022-12-31 | $43.76 Million | +13.64% |
| 2021-12-31 | $38.51 Million | +5.40% |
| 2020-12-31 | $36.54 Million | +11.90% |
| 2019-12-31 | $32.65 Million | -8.34% |
| 2018-12-31 | $35.62 Million | +42.32% |
| 2017-12-31 | $25.03 Million | -32.01% |
| 2015-12-31 | $36.81 Million | +17.97% |
| 2014-12-31 | $31.20 Million | +95.03% |
| 2013-12-31 | $16.00 Million | +148.29% |
| 2012-12-31 | $6.44 Million | -- |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more